Cost -effectiveness analysis on medication schemes for acute cerebral infarction under clinical pathway
Author(s): ZHANG Xiang-ju, ZHANG Ming-yan, GONG Yu-hang
Pages: 609-611
Year: 2014 Issue: 10
Journal: Qilu Pharmaceutical Affairs
Keyword: Clinical pathway; Acute cerebral infarction; Pharmacoeconomics; Cost - effectiveness analysis;
Abstract: Objective To analysis the cost - effectiveness on medication schemes for acute cerebral infarction under clinical pathway. Methods A total of 630 patients with acute cerebral infarction in four hospital from Jan 2012 to Jun 2013 were assigned into three groups,Z( Chinese patent medicine)group,210 cases;H( chemical)group,210 cases;L (drug combination)group,210 cases. The course of treatment was 14 days. A cost - effectiveness ananlysis of pharmacoeco-nomics was then conducted. Results The average cost of 3 groups was 3 235. 8 yuan,3 695. 04 yuan and 4 605. 8 yuan,the effective rate of 3 groups was 65. 24% ,77. 14% ,92. 86%. Conclusion Among the 3 schemes group L1 was the best one.
Pages: 609-611
Year: 2014 Issue: 10
Journal: Qilu Pharmaceutical Affairs
Keyword: Clinical pathway; Acute cerebral infarction; Pharmacoeconomics; Cost - effectiveness analysis;
Abstract: Objective To analysis the cost - effectiveness on medication schemes for acute cerebral infarction under clinical pathway. Methods A total of 630 patients with acute cerebral infarction in four hospital from Jan 2012 to Jun 2013 were assigned into three groups,Z( Chinese patent medicine)group,210 cases;H( chemical)group,210 cases;L (drug combination)group,210 cases. The course of treatment was 14 days. A cost - effectiveness ananlysis of pharmacoeco-nomics was then conducted. Results The average cost of 3 groups was 3 235. 8 yuan,3 695. 04 yuan and 4 605. 8 yuan,the effective rate of 3 groups was 65. 24% ,77. 14% ,92. 86%. Conclusion Among the 3 schemes group L1 was the best one.
Related Articles